Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Nov;20(11):102947.
doi: 10.1016/j.autrev.2021.102947. Epub 2021 Sep 10.

Post-COVID syndrome. A case series and comprehensive review

Affiliations
Meta-Analysis

Post-COVID syndrome. A case series and comprehensive review

Juan-Manuel Anaya et al. Autoimmun Rev. 2021 Nov.

Abstract

The existence of a variety of symptoms with a duration beyond the acute phase of COVID-19, is referred to as post-COVID syndrome (PCS). We aimed to report a series of patients with PCS attending a Post-COVID Unit and offer a comprehensive review on the topic. Adult patients with previously confirmed SARS-CoV-2 infection and PCS were systematically assessed through a semi-structured and validated survey. Total IgG, IgA and IgM serum antibodies to SARS-CoV-2 were evaluated by an electrochemiluminescence immunoassay. A systematic review of the literature and meta-analysis were conducted, following PRISMA guidelines. Univariate and multivariate methods were used to analyze data. Out of a total of 100 consecutive patients, 53 were women, the median of age was 49 years (IQR: 37.8-55.3), the median of post-COVID time after the first symptoms was 219 days (IQR: 143-258), and 65 patients were hospitalized during acute COVID-19. Musculoskeletal, digestive (i.e., diarrhea) and neurological symptoms including depression (by Zung scale) were the most frequent observed in PCS patients. A previous hospitalization was not associated with PCS manifestation. Arthralgia and diarrhea persisted in more than 40% of PCS patients. The median of anti-SARS-CoV-2 antibodies was 866.2 U/mL (IQR: 238.2-1681). Despite this variability, 98 patients were seropositive. Based on autonomic symptoms (by COMPASS 31) two clusters were obtained with different clinical characteristics. Levels of anti-SARS-CoV-2 antibodies were not different between clusters. A total of 40 articles (11,196 patients) were included in the meta-analysis. Fatigue/muscle weakness, dyspnea, pain and discomfort, anxiety/depression and impaired concentration were presented in more than 20% of patients reported. In conclusion, PCS is mainly characterized by musculoskeletal, pulmonary, digestive and neurological involvement including depression. PCS is independent of severity of acute illness and humoral response. Long-term antibody responses to SARS-CoV-2 infection and a high inter-individual variability were confirmed. Future studies should evaluate the mechanisms by which SARS-CoV-2 may cause PCS and the best therapeutic options.

Keywords: Long COVID; Post-COVID syndrome; Post-acute COVID-19; Prolonged COVID; anti-Sars-Cov-2 antibodies.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Fig. 1
Fig. 1
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow chart.
Fig. 2
Fig. 2
Acute and post-COVID symptoms. A. Frequency bar plot for clinical manifestations on acute COVID-19. B. Frequency bar plot for post-COVID clinical manifestations. Frequency of depression was estimated by Zung scale. C. Venn diagram with the superposition of the main PCS symptoms. Analysis included 91 patients, because 9 out of 100 patients did not exhibit any of the four main symptoms. D. Mirrored bar plot for symptoms on acute COVID-19 and post-COVID syndrome.
Fig. 3
Fig. 3
Anti RBD SARS-CoV-2 antibodies (see Supplementary Material 1 for details). A. Correlation between IgG anti-SARS-CoV-2 by ELISA (Euroimmun) and total anti-SARS-CoV-2 antibodies by ECLIA (Roche). B. Correlation between neutralizing anti-SARS-CoV-2 antibodies (PRNT50) and total anti-SARS-CoV-2 antibodies by ECLIA (Roche). C. Linear model for neutralizing antibodies based on ECLIA. D. ROC curve for the estimated cut-off value. The AUC represents the discrimination capacity of this threshold. E. Scatter plot for total anti-SARS-CoV-2 antibodies (by ECLIA, Roche) and post-COVID time. Line represents the locally estimated scatterplot smoothing with 95% confidence intervals.
Fig. 4
Fig. 4
Frequency bar plot for pooled prevalence of post-COVID manifestations in meta-analysis. Error bar represents the estimated 95% confidence interval. Only those clinical manifestations reported in more than 4 articles were included in this graph.
Fig. 5
Fig. 5
Autonomic clusters in post-COVID syndrome. A. Principal components of K-means clustering for weighted COMPASS 31 domains. COMPASS 31: composite autonomic symptom score 31. B. Mirrored bar plot for acute COVID-19 symptoms on cluster 1 and 2. C. Mirrored bar plot for post-COVID clinical manifestations on cluster 1 and 2.

References

    1. National Institute for Health and Care Excellence . NICE Guid. 2021. COVID-19 rapid guideline: Managing the long-term effects of COVID-19. - PubMed
    1. Acosta-Ampudia Y., Monsalve D.M., Rojas M., Rodríguez Y., Gallo J.E., Salazar-Uribe J.C., et al. COVID-19 convalescent plasma composition and immunological effects in severe patients. J Autoimmun. 2021;118:102598. doi: 10.1016/j.jaut.2021.102598. - DOI - PMC - PubMed
    1. Guan W., Ni Z., Hu Y., Liang W., Ou C., He J., et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed
    1. Lopez-Leon Sandra, Wegman-Ostrosky Talia, Perelman Carol, Sepulveda Rosalinda, Rebolledo Paulina A., Angelica Cuapio S.V. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. MedRxiv. 2021 doi: 10.1101/2021.01.27.21250617. - DOI - PMC - PubMed
    1. Goyal P., Choi J.J., Pinheiro L.C., Schenck E.J., Chen R., Jabri A., et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020;382:2372–2374. doi: 10.1056/NEJMc2010419. - DOI - PMC - PubMed